GCAR and Purdue initiate GBM AGILE trial of tinostamustine
The Global Coalition for Adaptive Research (GCAR) and Purdue Pharma have announced the activation of tinostamustine in the Glioblastoma Adaptive…
All articles by Salong Debbarma
Salong Debbarma
-
-
Hemispherian begins Phase I/IIa trial of GLIX1 for GBM
Hemispherian has initiated a first-in-human Phase I/IIa trial of its oral small molecule, GLIX1, in patients with recurrent and progressive…
-
NeuroTherapia concludes Phase IIa trial of NTRX-07 for Alzheimer’s
NeuroTherapia has concluded its Phase IIa clinical trial of NTRX-07, an orally available molecule, for Alzheimer's disease treatment. The randomised,…
-
First patient dosed in CatalYm’s Phase IIb visugromab trial
CatalYm has dosed the first patient in its Phase IIb GDFATHER-HCC-01 clinical trial, assessing visugromab, along with chemoimmunotherapy as a…
-
Amgen reports positive Phase III findings for subcutaneous Tepezza trial
Amgen has reported positive top line results from its Phase III subcutaneous Tepezza (teprotumumab-trbw) trial in adults with moderate-to-severe active…
-
Affinia gains Health Canada approval for UPBEAT Phase I/II trial
Affinia Therapeutics has received approval from Health Canada for its clinical trial application (CTA) to begin the UPBEAT Phase I/II…
-
Glycomine concludes Phase IIb POLAR study enrolment
Glycomine has concluded subject enrolment in the Phase IIb POLAR study of GLM101 to treat phosphomannomutase 2 congenital disorder of…
-
AstraZeneca reports positive EMERALD-3 results for HCC
AstraZeneca has reported positive high-level data from the EMERALD-3 Phase III trial, evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab), lenvatinib and…
-
Agenus enrols first patient in BATTMAN Phase III trial
Agenus has enrolled the first patient in the BATTMAN Phase III trial, assessing botensilimab (BOT) plus balstilimab (BAL) in refractory,…
-
Actinogen treats first patient in XanaMIA trial for Alzheimer’s
Actinogen has treated the first participant in the open-label extension (OLE) segment of its Phase IIb/III pivotal XanaMIA Alzheimer’s disease…